PI4861USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Alvaro et al. Serial No.: 10/520,143 Group Art Unit: 1614 File Date: January 17, 2006 Examiner: For: Substituted-4-Phenyl-Piperidin-Amides As Tachykinin Antagonists And Serotonin Reuptake Inhibitors Director of the U.S. Patent and Trademark Office P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

		opies of the references are enclosed: Ref. 4-12
1 :	98(d)) [] C	opies of the references were submitted in parent application (37 CFR
••	[]A R	copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have seen supplied to the U.S. Patent Office by the International Bureau.
A.	[X] OR	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	[]	The Information Disclosure Statement submitted herewith is being flied before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	(1	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an information Disclosure Statement under § 1.97(c) (\$180.00).
C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the international Search Report which

In accordance with the requirements of 37 CFR 1,97(d);

Issued on International Publication No.

ŝ

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

 [] A duplicate copy of this paper is attached.

Respectfully Sobmitted,

Lorie Ann Morgan

Registration No. 38,181

Date: 19 Jul 2006

GlaxoSmithKiine

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

	13-1			<u>-</u>			8	Sheet 1
om PTO-1		artment of Comme and Trademark Of	erce	ATTY DOCKET NO. SERIAL NO.				
INFORMATION DISCLOSURE				PI4661USW 10/520,143 APPLICANT				
	ATEMENT BY A			Alvaro et al.				
	(Use several sheets if n		FILING DATE Jenuary 17, 2006		GROUP 1614	,		
,		U.S. PA	ATEN	T DOCUMENTS		•		
Examiner Initials	Döcument Numbe	r Date		Name	Class	Subclass	Filing Oate	
7	US-3097209-A	07 -09 -1963 Ja	ansse	n et al.		i		
2	US-3843646-B	10 -22 -1974 G	3.D. S	earle and Co.				
3	US-6423519-B	07 -23 -2002 G	PÇ B	lotech Inc.				· <u></u>
						,		
						ş.		
								•
			N PA	TENT DOCUMENTS				
	Document Number	Date	,	Country	Class	Subclass	Translation Yes No	
4	BE-601228	03 -31 -1961 B	Έ		,		V	
5	DE-19603767-A	08 -07 -1997 D	E				V	
6	GB-1356118-A	06 -12 -1974 G	3					
7	WO-00 03743-A	01 -27 -2000 W	vo.					
ō	WO-03 039440-A	05 -15 -2003 W	/O					
9	WQ-03 048154-A	06 -12 -2003 W	/O					
				uthor, Title, Date, Pertinen				
10	CHÓDKOWSKI A. Pharmaceutica; 19	ET AL; Synthesis of som 79; 36(4); 439-42; EA	ne am NG/U ≨	ides of 1-butyl-4-phenylpiperidir bh Translation	ne-4-caroxylic ac	id; Acta Pok	oniae	
		•	ν.			1		-18
		· - ·						
		,		• 11		•		
						,		
aminer Sig	nature		Date	e Considered				
AMINER; Initi	al If reference considered, with include copy of this form with	hether or not citation is in	n conf	ormance with MPEP 609. Draw	line through cit	ation if not in	conform	nance and

							SI	neet <u>2</u> of <u>2</u>		
Form PTO-1449		U.S. Depa	artment of Commercand Trademark Offi	CE PI4861USW	SERIAL 10/520,	-				
INFORMATION DISCLOSURE				APPLICANT Alvaro et al.		1				
S	STATEMENT BY APPLICANT (Use several sheets if necessary)				FILING DATE GROUP January 17, 2006 1614 ;					
			U.S. PA1	ENT DOCUMENTS						
Examiner Initials	Document Numbe		Date	Name	Class	Subclass	Filing Date If Appropriate			
			<u> </u>	. <u>-</u>		,		.,,		
	 	+		100-		,				
	<u> </u>	<u>.</u>				ţ				
		 								
		 -			 -	,				
			FOREIGN	PATENT DOCUMENTS	. <u>. </u>					
	Document Number Date		Date	Country	Class	Subclass	Translation Yes No			
/ -	11	WO-04 020411-A	03 -11 -2004 WC)				•		
	12	WO-04 056771-A	07 -08 -2004 WC) <u> </u>		,				
						,				
						;				
						,				
-01		OTHER D	OCUMENTS (Includir	g Author, Title, Date, F	Pertinent Pages, Etc)		<u>'</u>			
		<u>.</u> .				;				
		<u> </u>								
·		1000	<u>-</u> -							
_						••••				
						,,,				
Examiner Signature Date				Date Considered	te Considered ,					
EXAMINER: I	Initial if refe d. Include	erence considered, who	ether or not citation is in one next communication to ap	conformance with MPEP 60 policant.	09. Draw line through cir	ation if not in	tonforme	ance and		